Search review questions

Functioning ‐ mean endpoint PSP (high = good) ‐ < 12 months · schizophrenia

Adverse events ‐ Participants with at least one AE ‐ > 1 year · schizophrenia

Mental state ‐ general: mean endpoint PANSS total (high = poor) ‐ < 12 months · schizophrenia

Global state ‐ number of participants with relapse/exacerbations of psychosis (separated time points) ‐ < 12 months · schizophrenia

Leaving the study early ‐ for any reason ‐ overall acceptability (separated time points) ‐ < 12 months · schizophrenia

Functioning ‐ mean endpoint functioning scales (high = good) ‐ < 12 months · schizophrenia

Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain intensity – as reported by the child, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Adverse events (reported in the first 7 days after the procedure) · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain intensity – as reported by the child, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain intensity – as reported by the child, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Adverse events (reported in the first 7 days after the procedure) · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain intensity – as reported by the child, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain intensity – as reported by the child, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Adverse events (reported in the first 7 days after the procedure) · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain intensity – as reported by the child, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain intensity – as reported by the child, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Adverse events (reported in the first 7 days after the procedure) · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Serious adverse events (defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016)) · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain intensity – as reported by the child, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Mean change from baseline in symptom scores at 1 to 4 weeks (lower is favored) · people with dry eye

Proportion of participants with intervention‐related, vision‐threatening adverse events at 1 to 4 weeks · people with dry eye

Mean change from baseline in meibomian gland expression scores at 1 to 4 weeks (higher is favored) · people with dry eye

Mean change from baseline in meibum quality scores at 1 to 4 weeks (higher is favored) · people with dry eye

Mean change from baseline in meibomian gland atrophy scores at 1 to 4 weeks (lower is favored) · people with dry eye

Proportion of participants with intervention‐related, vision‐threatening adverse events at 1 to 4 weeks · people with dry eye

Mean change from baseline in symptom scores at 1 to 4 weeks (lower is favored) · people with dry eye

Mean change from baseline in meibomian gland expression scores at 1 to 4 weeks (higher is favored) · people with dry eye

Mean change from baseline in meibum quality scores at 1 to 4 weeks (higher is favored) · people with dry eye

Mean change from baseline in meibomian gland atrophy scores at 1 to 4 weeks (lower is favored) · people with dry eye

Proportion of eyes with retinal displacement at 6 months or later (RR < 1 favored) · people with primary macula‐involving rhegmatogenous retinal detachments

Mean change in logMAR or Snellen visual acuity from baseline to 3 months or later (lower is favored) · people with primary macula‐involving rhegmatogenous retinal detachments

Mean objective distortion score at 3 months or later (lower is favored) · people with primary macula‐involving rhegmatogenous retinal detachments

Quality of life assessments at 3 months or later (higher is favored) · people with primary macula‐involving rhegmatogenous retinal detachments

Frequency of intervention‐related ocular adverse events ( · people with primary macula‐involving rhegmatogenous retinal detachments

Frequency of intervention‐related non‐ocular adverse events ( · people with primary macula‐involving rhegmatogenous retinal detachments

Dialysis dysequilibrium syndrome · haemodialysis patients

Duration of hospital stay ‐ not reported · haemodialysis patients

Severe dialysis dysequilibrium syndrome · haemodialysis patients

Death · haemodialysis patients